OakChart

Soligenix Inc

SNGXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:58 PM ET

0.3213+0.0012 (0.37%)
2026-11-12 05:24 CET
Market cap
7.51 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-8.83 USD m
Free cash flow, TTM
-8.24 USD m
EPS diluted, TTM
-0.74
P/E
-
Compare

Price

SNGX against its 20, 50 and 200-day averages
2050200beatearnings
0.501.001.50123.3M246.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SNGXclose 0.3220-day 0.3550-day 0.36200-day 0.640.32

81.1% under the 52-week high of 1.70 on 12 Dec 2025. 52-week low 0.28 on 11 May 2026. Last 15 sessions, 20.4% high to low

Volume 0.32× normal · the line is the 50-bar volume average

Profile

SNGX
52-week range, 3% of the way up
0.281.70

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Employees14
IPOApr 04, 1994
Beta2.05
ATR, 14d0.02
Rel volume0.32
Short float0.30%
Insider own4.59%
Inst own4.23%

Snapshot

6 groups

Valuation

Index-
Market Cap7.51M
Enterprise Value-1.24M
Income-8.83M
Sales0.00M
Book/sh0.27
Cash/sh0.39
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPOApr 04, 1994

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.20
P/C0.83
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.99
Current Ratio2.99
Debt/Eq0.04
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.74
EPS next Y-0.25
EPS next Q-0.09
EPS this Y81.31%
EPS next Y37.50%
EPS next 5Y-
EPS past 3/5Y69.72% 57.52%
Sales past 3/5Y- -
EPS Y/Y TTM79.77%
Sales Y/Y TTM-
EPS Q/Q91.36%
Sales Q/Q-
EarningsNov 06 BMO
EPS/Sales Surpr.52.38% -

Ownership

Insider Own4.59%
Insider Trans0.00%
Inst Own4.23%
Inst Trans9.57%
ROA-85.03%
ROE-127.42%
ROIC-137.79%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-8.45%
SMA50-10.81%
SMA200-49.76%
Trades-

Technical

Shs Outstand23.37M
Shs Float22.30M
Short Float0.30%
Short Ratio0.35
Short Interest0.07M
52W High1.70 -81.04%
52W Low0.28 14.75%
Volatility6.18% 6.20%
ATR (14)0.02
RSI (14)36.70
Beta2.05
Rel Volume0.32
Avg Volume192.03K
Volume62,366

Performance

Perf Week-8.41%
Perf Month-4.03%
Perf Quarter-15.65%
Perf Half Y-11.44%
Perf YTD-76.02%
Perf Year-77.37%
Perf 3Y-95.23%
Perf 5Y-99.85%
Perf 10Y-99.96%
Recom1.00
Target Price1.50
Prev Close0.32
Price0.32
Change %0.37%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Jul 28, 2020DowngradeDDawson JamesBuy → Neutral
Jan 31, 2018DowngradeHH.C. WainwrightBuy → Neutral$5.50 → $2.70+740.3%
Aug 14, 2017ReiteratedMMaxim GroupBuy$4 → $5+1,456.2%
Jul 17, 2017InitiatedHH.C. WainwrightBuy$11+3,323.6%

Peers

Mkt cap
TickerCompanyMkt cap
CTXRCitius Pharmaceuticals Inc13.20M
VRCAVerrica Pharmaceuticals Inc67.17M
AIMAIM ImmunoTech Inc5.93M
GOVXGeovax Labs Inc1.10M
DRMADermata Therapeutics Inc3.54M
EDSAEdesa Biotech Inc29.99M
CUVLClinuvel Pharmaceuticals Ltd ADR256.99M
ACRSAclaris Therapeutics Inc688.38M
NNVCNanoViricides Inc35.23M
TLSATiziana Life Sciences Ltd79.68M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-06-0.050-0.105-0.1200.000.002
2026Q22026-08-07-0.120-0.155-0.1250.000.002
2026Q12026-05-08-0.280-0.270-0.2780.000.002
2025Q42026-03-310.320-0.555-0.2870.000.002
2025Q32025-11-07-0.580-0.555-0.5850.000.002
2025Q22025-08-14-0.820-0.920-0.8240.000.002
2025Q12025-05-09-1.060--1.0610.00--
2024Q42025-03-21-1.130-0.950-1.1880.200.201
2024Q32024-11-08-0.780-1.390-0.7800.000.202
2024Q22024-08-09-1.310-1.775-1.3060.100.202
2024Q12024-05-10-2.880-3.040-2.9130.100.202
2023Q42024-03-15-0.800-3.200-2.8060.240.201
2023Q32023-11-13-2.560-2.240-2.5630.100.201
2023Q22023-08-21-3.520-4.320-3.5590.200.001
2023Q12023-05-15-5.760-20.000-5.7420.300.20-
2022Q42023-03-31-19.360-16.800-20.8320.160.201

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-272.4-292.8-321.610.456.85
2017FY-278.4-260.4-278.45.405.80
2018FY-163.2-150.4-162.095.204.37
2019FY-115.2-115.2-115.884.603.79
2020FY-153.6-120.48-154.452.402.20
2021FY-74.400-69.600-75.0580.800.67
2022FY-76.960-72.000-76.8890.950.78
2023FY-12.640-13.280-12.6650.840.80
2024FY-6.100--4.9790.10-
2025FY-2.140-2.150-12.8000.100.00
2026FY--0.400---
2027FY--0.250---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-061000.000.000.00
2026Q4S2026-08-071000.000.000.00
2026Q4S2026-05-081000.000.000.00
2026Q4S2026-04-061000.000.000.00
2026Q4R2026-11-06100-0.10-0.10-0.10
2026Q4R2026-10-26100-0.10-0.10-0.10
2026Q4R2026-08-12110-0.10-0.10-0.10
2026Q4R2026-08-07100-0.21-0.21-0.21
2026Q4R2026-07-28100-0.21-0.21-0.21
2026Q4R2026-05-14110-0.21-0.21-0.21
2026Q4R2026-05-08100-0.25-0.25-0.25
2026Q4R2026-04-06100-0.25-0.25-0.25
2026Q4E2026-11-06200-0.09-0.10-0.07
2026Q4E2026-10-26200-0.09-0.10-0.07

Estimate history

EPS, annual-278.4-162.086-115.879-154.445-75.058-76.889-12.665-4.979-2.135-0.7401
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.78-1.188-1.061-0.824-0.585-0.287-0.278-0.125-0.051
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual5.4323.9653.2161.9310.0330.250000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0360.0740.0910.1280.1790.1820.6492.51410.08623.369
Period201720182019202020212022202320242025MRQ
Shares, quarterly2.2952.5143.1843.5059.86110.08610.51821.63723.369
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.250.031.933.223.97
Cost of Goods Sold Incl. D&A0.000.000.130.750.570.751.863.574.60
Gross Profit-0.00-0.00-0.13-0.75-0.32-0.710.07-0.35-0.63
Selling, General and Administrative Excl. Other9.8311.849.437.7914.3512.8718.8910.749.70
Research and Development5.397.485.223.317.668.0214.917.266.75
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.83-11.85-9.56-8.54-14.67-13.58-18.82-11.09-10.33
Interest Expense---0.050.820.860.01-0.00
Unusual Expense-0.240.00-0.570.230.00-0.420.00--
Net Income Before Taxes-9.33-11.59-8.65-7.93-14.82-13.24-18.43-9.53-8.90
Income Taxes-0.51-0.51-0.38-1.79-1.02-0.69-0.74-0.180.00
Consolidated Net Income-8.83-11.08-8.27-6.14-13.80-12.55-17.69-9.36-8.90
Net Income From Continuing Operations-8.83-11.08-8.27-6.14-13.80-12.55-17.69-9.36-8.90
Net Income-8.83-11.08-8.27-6.14-13.80-12.55-17.69-9.36-8.90
EPS (Recurring)-0.41-2.14-5.22-12.33-76.89-76.82-154.45-115.88-162.09
EPS (Basic, Before Extraordinaries)-0.74-2.14-4.98-12.66-76.89-75.06-154.44-115.88-162.09
EPS (Diluted)-0.74-2.14-4.98-12.66-76.89-75.06-154.44-115.88-162.09
EBITDA-9.83-11.84-9.55-8.42-14.53-13.43-18.63-10.91-10.29
Non-Operating Income (Expense)0.260.260.330.880.670.780.411.561.43
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.580.460.260.290.260.260.300.270.38
Price To Sales Ratio----77.87794.5618.228.742.86
Gross Margin-----127.05-2,140.723.47-10.94-15.94
Operating Margin-----5,868.83-40,725.20-975.10-344.82-260.62
Net Margin-----5,519.34-37,632.97-916.25-290.94-224.44
Shares Outstanding23.3710.092.510.650.180.180.130.090.07
Market Capitalization7.517.516.767.8619.4828.2839.1831.5115.19

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other1.372.102.883.472.582.763.313.71
Research and Development0.360.971.782.281.581.682.232.66
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.38-2.10-2.88-3.47-2.58-2.76-3.31-3.71
Unusual Expense-0.18-0.060.000.000.000.000.00-0.25
Net Income Before Taxes-1.12-1.99-2.82-3.40-2.53-2.70-3.24-3.40
Income Taxes0.000.000.00-0.510.000.000.00-0.41
Consolidated Net Income-1.12-1.99-2.82-2.90-2.53-2.70-3.24-2.99
Net Income From Continuing Operations-1.12-1.99-2.82-2.90-2.53-2.70-3.24-2.99
Net Income-1.12-1.99-2.82-2.90-2.53-2.70-3.24-2.99
EPS (Recurring)-0.06-0.13-0.28-0.29-0.58-0.82-1.06-1.26
EPS (Basic, Before Extraordinaries)-0.05-0.12-0.28-0.29-0.58-0.82-1.06-1.19
EPS (Diluted)-0.05-0.12-0.28-0.29-0.58-0.82-1.06-1.19
EBITDA-1.37-2.10-2.88-3.47-2.58-2.76-3.31-3.71
Non-Operating Income (Expense)0.080.050.060.070.050.060.080.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.090.120.120.250.100.100.060.16
Shares Outstanding23.3721.6410.5210.099.863.503.182.51
Market Capitalization7.515.8711.9013.524.974.286.786.76

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.947.828.4513.3626.0418.685.428.987.81
Short Term Receivables0.000.000.200.220.240.561.461.201.34
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.890.910.870.270.280.230.610.160.26
Total Current Assets8.838.729.5113.8526.5719.477.4910.349.42
Net Property, Plant & Equipment0.360.120.240.360.130.250.160.020.04
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable-0.000.030.020.120.07---
Intangible Assets0.000.000.000.00-0.000.020.050.07
Other Assets0.040.130.020.040.050.100.100.080.02
Total Assets9.248.979.8014.2826.8719.897.7810.499.55
Short Term Debt Incl. Current Port. of LT Debt0.111.482.3710.010.110.440.120.000.00
Accounts Payable1.120.671.113.872.932.132.742.131.75
Other Current Liabilities2.472.702.672.643.263.513.462.091.48
Total Current Liabilities3.704.856.1516.526.296.086.314.213.23
Long Term Debt0.240.001.120.239.8610.070.010.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities3.944.857.2716.7516.1516.156.324.213.23
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity5.294.122.52-2.4710.723.741.466.286.32
Total Shareholders Equity5.294.122.52-2.4710.723.741.466.286.32
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity5.294.122.52-2.4710.723.741.466.286.32
Total Liabilities & Stockholders Equity9.248.979.8014.2826.8719.897.7810.499.55
Book Value Per Share0.521.643.89-13.5960.0229.3116.0885.24173.73
Tangible Book Value Per Share0.521.643.89-13.5960.0229.3115.8684.60171.69
Full-Time Employees141615151518161418
Price to Book Ratio1.201.041.8618.882.6410.4721.622.424.18
Return on Assets-121.75-88.11-51.01-67.06-53.68-127.87-102.43-88.82-72.13
Return on Equity-235.50-248.97-23,783.30-334.43-173.54-680.46-241.83-141.27-104.21
Return on Invested Capital-200.14-200.74-168.46--60.99-128.08-639.36-141.72-113.09
Quick Ratio2.391.801.550.844.223.201.192.462.92
Current Ratio2.391.801.550.844.223.201.192.462.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.83-11.08-8.27-6.14-13.80-12.55-17.69-9.36-8.90
Depreciation0.000.000.010.120.140.150.190.180.04
Other Funds (Non Cash)0.530.780.210.860.590.015.530.530.38
Funds from Operations-8.29-10.30-8.06-5.17-13.07-12.39-11.96-8.65-8.47
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.050.03-0.35-3.440.430.650.511.141.23
Cash from Operating Activities-8.23-10.27-8.40-8.60-12.65-11.74-11.45-7.51-7.24
Capital Expenditures-0.00-0.010.000.00-0.01-0.01-0.01-0.03-0.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.010.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.010.000.00-0.01-0.01-0.01-0.02-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock6.7311.769.1310.660.0819.1114.414.018.42
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock6.7311.769.1310.660.0819.1114.414.018.42
Proceedsfrom Stock Options6.4311.464.6810.660.0819.0813.554.018.42
Issuance or Reduction of Debt, Net0.00-1.37-1.37-7.000.00-0.019.85-0.010.00
Change in Long Term Debt0.00-1.37-1.37-7.000.00-0.019.85-0.010.00
Issuance of Long Term Debt0.000.000.000.000.000.009.860.000.00
Reduction of Long Term Debt0.00-1.37-1.37-7.000.00-0.01-0.01-0.010.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.420.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities6.7310.397.763.660.0819.0624.684.018.42
Exchange Rate Effect-0.000.010.03-0.100.060.04-0.03-0.00
Net Change in Cash-1.500.12-0.63-4.91-12.687.3713.26-3.561.17
Free Cash Flow-8.24-10.27-8.40-8.60-12.66-11.75-11.46-7.54-7.25
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments9.029.816.037.9410.535.10
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.140.360.440.890.360.19
Total Current Assets9.1610.176.478.8310.885.29
Net Property, Plant & Equipment0.270.300.330.360.390.42
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.030.030.120.040.020.05
Total Assets9.4610.506.929.2411.295.76
Short Term Debt Incl. Current Port. of LT Debt0.120.120.120.110.110.11
Accounts Payable1.711.410.831.121.210.65
Other Current Liabilities1.222.142.672.472.102.87
Total Current Liabilities3.063.673.623.703.423.63
Long Term Debt0.150.180.210.240.270.30
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.213.853.833.943.703.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity6.266.653.095.297.601.83
Total Shareholders Equity6.266.653.095.297.601.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity6.266.653.095.297.601.83
Total Liabilities & Stockholders Equity9.4610.506.929.2411.295.76
Book Value Per Share0.270.310.290.520.770.52
Tangible Book Value Per Share0.270.310.290.520.770.52
Full-Time Employees---14--
Price to Book Ratio1.201.352.251.742.221.15
Return on Assets-85.03-125.95-149.35-124.89-105.25-136.26
Return on Equity-127.42-241.65-326.87-241.57-169.32-402.19
Return on Invested Capital-17.45-29.11-85.52-52.31-32.15-126.76
Quick Ratio2.992.771.792.393.181.46
Current Ratio2.992.771.792.393.181.46

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.12-1.99-2.82-2.90-2.53-2.42
Depreciation0.000.000.000.000.000.00
Other Funds (Non Cash)-0.120.150.160.350.180.13
Funds from Operations-1.24-1.84-2.66-2.55-2.35-2.29
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.190.130.31-0.20-0.58-0.45
Cash from Operating Activities-1.42-1.71-2.36-2.75-2.93-2.74
Capital Expenditures0.000.000.00-0.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.645.490.450.168.360.55
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.645.490.450.168.360.55
Proceedsfrom Stock Options0.645.490.45-0.158.360.55
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.645.490.450.168.360.55
Exchange Rate Effect---0.000.000.00
Net Change in Cash-0.793.78-1.91-2.595.43-2.20
Free Cash Flow-1.42-1.71-2.36-2.75-2.93-2.75

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 119.37K
United States2024: 119.37K
Specialized BioTherapeutics2024: 119.37K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.32%0.1M20.8M196.92K
2026-10-150.78%0.2M20.8M236.72K
2026-09-300.81%0.2M20.8M288.93K
2026-09-150.98%0.2M20.8M354.13K
2026-08-311.01%0.2M20.8M966.43K
2026-08-141.00%0.2M20.8M7.01M
2026-07-312.88%0.6M20.3M7.16M
2026-07-153.50%0.5M13.8M7.59M
2026-06-302.96%0.4M13.8M7.42M
2026-06-153.23%0.5M14.8M7.28M
2026-05-2944.01%6.5M14.8M6.77M
2026-05-154.70%0.7M14.8M709.56K
2026-04-309.93%1.0M10.3M559.30K
2026-04-157.86%0.8M10.3M221.79K
2026-03-316.44%0.7M10.3M225.86K
2026-03-136.25%0.6M10.1M237.77K
2026-02-276.82%0.7M10.1M271.21K
2026-02-136.01%0.6M10.1M289.80K
2026-01-304.90%0.5M10.1M306.80K
2026-01-154.52%0.5M10.1M327.05K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06424B3SEC
2026-11-06424B3SEC
2026-11-06424B3SEC
2026-11-06424B3SEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-02SCHEDULE 13G/ASEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-09-218-KCurrent report2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-08-07424B3SEC
2026-08-07424B3SEC
2026-08-07424B3SEC
2026-08-07424B3SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03ARSAnnual report to security holders. 2025-12-31SEC
2026-08-03DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-03DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-07-23PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-21PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-17SEC
2026-06-268-KCurrent report2026-06-26SEC
2026-06-26424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC1.41%
JANE STREET GROUP, LLC1.40%
XTX Topco Ltd1.06%
VANGUARD CAPITAL MANAGEMENT LLC0.55%
GEODE CAPITAL MANAGEMENT, LLC0.49%
Virtu Financial LLC0.41%
VANGUARD FIDUCIARY TRUST CO0.36%
StoneX Group Inc.0.26%
NORTHERN TRUST CORP0.26%
CITIGROUP INC0.05%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.55%
Fidelity Extended Market Index Fund0.35%
Fidelity Series Total Market Index Fund0.07%
Fidelity Total Market Index Fund0.04%

OakChart. SNGX. Cached 15 minutes.

Some panels did not load: insider.